{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:17:22Z","timestamp":1780467442783,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fondo para la Convergencia Estructural del Mercosur","award":["COF 03\/11"],"award-info":[{"award-number":["COF 03\/11"]}]},{"name":"Fondo para la Convergencia Estructural del Mercosur","award":["COF 03\/11"],"award-info":[{"award-number":["COF 03\/11"]}]},{"name":"Sistema Nacional de Investigadores, Agencia Nacional de Investigaci\u00f3n e Innovaci\u00f3n"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["VR3-172639"],"award-info":[{"award-number":["VR3-172639"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["VR3-172639"],"award-info":[{"award-number":["VR3-172639"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007711","name":"British Columbia Knowledge Development Fund","doi-asserted-by":"publisher","award":["36194"],"award-info":[{"award-number":["36194"]}],"id":[{"id":"10.13039\/501100007711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC-2020-00007"],"award-info":[{"award-number":["CRC-2020-00007"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36842-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:05:26Z","timestamp":1770059126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Jason R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelen","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Kovacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Gueron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Cherkasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"36842_CR1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.2023.19542","volume":"330","author":"KW Chew","year":"2023","unstructured":"Chew, K. W., Malani, P. N. & Gandhi, R. T. COVID-19 therapeutics for nonhospitalized patients: Updates and future directions. JAMA 330, 1519\u20131520 (2023).","journal-title":"JAMA"},{"key":"36842_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386, 1397\u20131408 (2022).","journal-title":"N Engl J Med"},{"issue":"13","key":"36842_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","volume":"390","author":"Hammond","year":"2024","unstructured":"Hammond, et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. New England J. Med. 390(13), 1186\u20131195 (2024).","journal-title":"New England J. Med."},{"key":"36842_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","volume":"42","author":"MM Foisy","year":"2008","unstructured":"Foisy, M. M., Yakiwchuk, E. M. & Hughes, C. A. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42, 1048\u20131059 (2008).","journal-title":"Ann. Pharmacother."},{"key":"36842_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","volume":"31","author":"O Kis","year":"2010","unstructured":"Kis, O., Robillard, K., Chan, G. N. & Bendayan, R. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 31, 22\u201335 (2010).","journal-title":"Trends Pharmacol Sci"},{"key":"36842_CR6","first-page":"e37153","volume":"15","author":"B Casey 3rd","year":"2023","unstructured":"Casey, B. 3rd., Vernick, R. C., Bahekar, A., Patel, D. & Ncogo Alene, I. Ranolazine Toxicity Secondary to Paxlovid. Cureus 15, e37153 (2023).","journal-title":"Cureus"},{"issue":"5","key":"36842_CR7","doi-asserted-by":"publisher","first-page":"030006052412477","DOI":"10.1177\/03000605241247705","volume":"52","author":"D Shen","year":"2024","unstructured":"Shen, D., Gong, Y., Qian, Y., Zhu, J. & Gao, J. Nirmatrelvir\/ritonavir treatment of patients with COVID-19 taking tacrolimus: Case series describing the results of drug\u2013drug interactions. J. Int. Med. Res. 52(5), 03000605241247705 (2024).","journal-title":"J. Int. Med. Res."},{"key":"36842_CR8","first-page":"e35489","volume":"15","author":"S Michael","year":"2023","unstructured":"Michael, S., Heilbronner, R., Lloyd, C. M. & Levitin, H. W. Paxlovid-induced tacrolimus toxicity in the treatment of COVID-19: A case report. Cureus 15, e35489 (2023).","journal-title":"Cureus"},{"key":"36842_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.23876\/j.krcp.22.218","volume":"41","author":"E-J Kwon","year":"2022","unstructured":"Kwon, E.-J. et al. Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir\/ritonavir) administration in a kidney transplant recipient. Kidney Res Clin Pract 41, 768\u2013770 (2022).","journal-title":"Kidney Res Clin Pract"},{"key":"36842_CR10","doi-asserted-by":"publisher","first-page":"2246594","DOI":"10.1080\/22221751.2023.2246594","volume":"12","author":"J P\u00e9rez-Vargas","year":"2023","unstructured":"P\u00e9rez-Vargas, J. et al. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Emerg Microbes Infect 12, 2246594 (2023).","journal-title":"Emerg Microbes Infect"},{"key":"36842_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/med.21783","volume":"41","author":"M Xiong","year":"2021","unstructured":"Xiong, M., Su, H., Zhao, W., Xie, H. & Shao, Q. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design. Med Res Rev 41, 1965\u20131998 (2021).","journal-title":"Med Res Rev"},{"key":"36842_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/v16060844","volume":"16","author":"VMdF Amorim","year":"2024","unstructured":"Amorim, VMd. F. et al. 3-Chymotrypsin-like protease (3CLpro) of SARS-CoV-2: Validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials. Viruses 16, 844 (2024).","journal-title":"Viruses"},{"key":"36842_CR13","doi-asserted-by":"publisher","first-page":"107587","DOI":"10.1016\/j.pharmthera.2020.107587","volume":"213","author":"T Liu","year":"2020","unstructured":"Liu, T., Luo, S., Libby, P. & Shi, G.-P. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacol. Ther. 213, 107587 (2020).","journal-title":"Pharmacol. Ther."},{"key":"36842_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"36842_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/1568026621666210119111409","volume":"21","author":"DA Sabbah","year":"2021","unstructured":"Sabbah, D. A., Hajjo, R., Bardaweel, S. K. & Zhong, H. A. An updated review on betacoronavirus viral entry inhibitors: Learning from past discoveries to advance COVID-19 drug discovery. Curr Top Med Chem 21, 571\u2013596 (2021).","journal-title":"Curr Top Med Chem"},{"key":"36842_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/v12080880","volume":"12","author":"RW K\u00f6rner","year":"2020","unstructured":"K\u00f6rner, R. W., Majjouti, M., Alcazar, M. A. A. & Mahabir, E. Of mice and men: The coronavirus MHV and Mouse models as a translational approach to understand SARS-CoV-2. Viruses 12, 880 (2020).","journal-title":"Viruses"},{"key":"36842_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12250-014-3530-y","volume":"29","author":"Z Yang","year":"2014","unstructured":"Yang, Z. et al. Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL\/6 mice. Virologica Sinica 29, 393\u2013402 (2014).","journal-title":"Virologica Sinica"},{"key":"36842_CR18","doi-asserted-by":"publisher","first-page":"7132","DOI":"10.1038\/s41598-021-86679-0","volume":"11","author":"AP Ar\u00e9valo","year":"2021","unstructured":"Ar\u00e9valo, A. P. et al. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Sci. Rep. 11, 7132 (2021).","journal-title":"Sci. Rep."},{"key":"36842_CR19","unstructured":"Chaves, I.d.M. et al. Broad-Spectrum Antiviral Efficacy of 7-Deaza-7-Fluoro-2\u2019-C-Methyladenosine Against Multiple Coronaviruses In Vitro and In Vivo. bioRxiv, 2025.01.02.631052 (2025)."},{"issue":"1","key":"36842_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/mps5010005","volume":"5","author":"T Shuipys","year":"2022","unstructured":"Shuipys, T. & Montazeri, N. Optimized protocols for the propagation and quantification of infectious murine hepatitis virus (MHV-A59) Using NCTC clone 1469 and 929 cells. Methods Protoc. 5(1), 5 (2022).","journal-title":"Methods Protoc."},{"key":"36842_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/1872208316666220124101611","volume":"16","author":"S Sonia","year":"2022","unstructured":"Sonia, S., Aman, K. & Himanshu, S. In-vitro and In-vivo experimental models for MERS-CoV, SARSCoV, and SARS-CoV-2 viral infection: A compendious review. Recent Pat. Biotechnol. 16, 82\u2013101 (2022).","journal-title":"Recent Pat. Biotechnol."},{"key":"36842_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1039\/D1MD00247C","volume":"12","author":"B Bai","year":"2021","unstructured":"Bai, B. et al. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. RSC Med. Chem. 12, 1722\u20131730 (2021).","journal-title":"RSC Med. Chem."},{"key":"36842_CR23","doi-asserted-by":"publisher","first-page":"12733","DOI":"10.1002\/anie.201806966","volume":"57","author":"Z Yuan","year":"2018","unstructured":"Yuan, Z. et al. Site-selective, late-stage C\u2212H 18F-fluorination on unprotected peptides for positron emission tomography imaging. Angew. Chem. Int. Ed. 57, 12733\u201312736 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"36842_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00726-015-1920-6","volume":"47","author":"AJ Lee","year":"2015","unstructured":"Lee, A. J. et al. A 14C-leucine absorption, distribution, metabolism and excretion (ADME) study in adult Sprague-Dawley rat reveals \u03b2-hydroxy-\u03b2-methylbutyrate as a metabolite. Amino Acids 47, 917\u2013924 (2015).","journal-title":"Amino Acids"},{"key":"36842_CR25","doi-asserted-by":"publisher","first-page":"103021","DOI":"10.1016\/j.bioorg.2019.103021","volume":"89","author":"A Kumari","year":"2019","unstructured":"Kumari, A. & Singh, R. K. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorg. Chem. 89, 103021 (2019).","journal-title":"Bioorg. Chem."},{"key":"36842_CR26","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/cbic.201800768","volume":"20","author":"VM Norwood IV","year":"2019","unstructured":"Norwood, V. M. IV. & Huigens, R. W. III. Harnessing the chemistry of the indole heterocycle to drive discoveries in biology and medicine. ChemBioChem 20, 2273\u20132297 (2019).","journal-title":"ChemBioChem"},{"key":"36842_CR27","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ejmech.2019.07.019","volume":"180","author":"PV Thanikachalam","year":"2019","unstructured":"Thanikachalam, P. V., Maurya, R. K., Garg, V. & Monga, V. An insight into the medicinal perspective of synthetic analogs of indole: A review. Eur. J. Med. Chem. 180, 562\u2013612 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"36842_CR28","doi-asserted-by":"publisher","first-page":"115758","DOI":"10.1016\/j.ejmech.2023.115758","volume":"260","author":"N Sheikhi","year":"2023","unstructured":"Sheikhi, N., Bahraminejad, M., Saeedi, M. & Mirfazli, S. S. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022. Eur. J. Med. Chem. 260, 115758 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"36842_CR29","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","volume":"61","author":"NA Meanwell","year":"2018","unstructured":"Meanwell, N. A. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. J. Med. Chem. 61, 5822\u20135880 (2018).","journal-title":"J. Med. Chem."},{"key":"36842_CR30","doi-asserted-by":"publisher","first-page":"10633","DOI":"10.1021\/acsomega.0c00830","volume":"5","author":"M Inoue","year":"2020","unstructured":"Inoue, M., Sumii, Y. & Shibata, N. Contribution of organofluorine compounds to pharmaceuticals. ACS Omega 5, 10633\u201310640 (2020).","journal-title":"ACS Omega"},{"key":"36842_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1021\/acsmedchemlett.3c00542","volume":"15","author":"DR Weiss","year":"2024","unstructured":"Weiss, D. R. et al. Balanced permeability index: A multiparameter index for improved in vitro permeability. ACS Med. Chem. Lett. 15, 457\u2013462 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"36842_CR32","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1021\/acs.jcim.4c02212","volume":"65","author":"CP Spielvogel","year":"2025","unstructured":"Spielvogel, C. P. et al. Enhancing blood-brain barrier penetration prediction by machine learning-based integration of novel and existing, in silico and experimental molecular parameters from a standardized database. J. Chem. Inf. Model. 65, 2773\u20132784 (2025).","journal-title":"J. Chem. Inf. Model."},{"key":"36842_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","volume":"7","author":"TT Wager","year":"2016","unstructured":"Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Central nervous system multiparameter optimization desirability: Application in drug discovery. ACS Chem. Neurosci. 7, 767\u2013775 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"36842_CR34","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1038\/s41467-023-41298-3","volume":"14","author":"VV Levterov","year":"2023","unstructured":"Levterov, V. V. et al. 2-Oxabicyclo[2.2.2]octane as a new bioisostere of the phenyl ring. Nat. Commun. 14, 5608 (2023).","journal-title":"Nat. Commun."},{"issue":"19","key":"36842_CR35","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2174\/1568026619666190712205025","volume":"19","author":"M de Sena","year":"2019","unstructured":"de Sena, M. et al. The Use of conformational restriction in medicinal chemistry. Current Topics Med. Chem. 19(19), 1712\u20131733 (2019).","journal-title":"Current Topics Med. Chem."},{"key":"36842_CR36","doi-asserted-by":"publisher","first-page":"e21573","DOI":"10.1096\/fj.202100280RR","volume":"35","author":"S Yan","year":"2021","unstructured":"Yan, S. & Wu, G. Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development. FASEB J. 35, e21573 (2021).","journal-title":"FASEB J."},{"key":"36842_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang, Y., Yang, C., Xu, X.-F., Xu, W. & Liu, S.-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141\u20131149 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"36842_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.121.000801","volume":"50","author":"H Eng","year":"2022","unstructured":"Eng, H. et al. Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-Like Protease, across animals and humans. Drug Metab. Dispos. 50, 576\u2013590 (2022).","journal-title":"Drug Metab. Dispos."},{"key":"36842_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41419-024-07247-8","volume":"15","author":"A Toro","year":"2024","unstructured":"Toro, A. et al. Blood matters: the hematological signatures of Coronavirus infection. Cell Death Dis. 15, 863 (2024).","journal-title":"Cell Death Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36842-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:48:37Z","timestamp":1771415317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36842-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36842"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36842-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RNY is founder and president of Mesentech which is not affiliated with this research. RNY and AC are members of the scientific advisory board of Variational AI, Inc. which is not affiliated with this research. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6905"}}